David Readett

739 total citations
17 papers, 573 citations indexed

About

David Readett is a scholar working on Oncology, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, David Readett has authored 17 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Genetics and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in David Readett's work include Hemoglobinopathies and Related Disorders (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). David Readett is often cited by papers focused on Hemoglobinopathies and Related Disorders (5 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). David Readett collaborates with scholars based in United States, United Kingdom and Australia. David Readett's co-authors include G. R. Serjeant, Vera Hirsh, Sandra J. Meech, J Morris, Rebecca Benner, Arthur Μ. Krieg, Donald Woytowitz, Mohammed Al-Adhami, Christian Manegold and J. Mezger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

David Readett

17 papers receiving 550 citations

Peers

David Readett

IMMUN

ONCOL

UROLO

PRM

Emilia Salzmann‐Manrique Germany

Beth Colombe United States

R Destro Italy

Caterina Micò Italy

Antonio Traficante Italy

Naoko Kinukawa Japan

Arabella Neva Italy

Hemalatha G. Rangarajan United States

Petter Svenberg Sweden

A D'agata Italy

Emilia Salzmann‐Manrique Germany

David Readett

174 ×0.6

IMMUN

177 ×1.0

ONCOL

78 ×0.7

13 ×0.2

UROLO

54 ×0.7

PRM

Citations per year, relative to David Readett David Readett (= 1×) peers Emilia Salzmann‐Manrique

Countries citing papers authored by David Readett

Since Specialization

Citations

This map shows the geographic impact of David Readett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Readett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Readett more than expected).

Fields of papers citing papers by David Readett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Readett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Readett. The network helps show where David Readett may publish in the future.

Co-authorship network of co-authors of David Readett

This figure shows the co-authorship network connecting the top 25 collaborators of David Readett. A scholar is included among the top collaborators of David Readett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Readett. David Readett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Dampier, Carlton, Marilyn J. Telen, Ted Wun, et al.. (2022). A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood. 141(2). 168–179. 28 indexed citations

Dampier, Carlton, Marilyn J. Telen, Ted Wun, et al.. (2020). Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood. 136(Supplement 1). 18–19. 9 indexed citations

Ryan, Kelly A., Anna Plotka, Frank Shafer, et al.. (2020). Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel. Clinical Pharmacology in Drug Development. 9(8). 918–928. 2 indexed citations

Plotka, Anna, et al.. (2017). Lack of Effect of Rivipansel on QTc Interval in Healthy Adult African American Male Subjects. The Journal of Clinical Pharmacology. 57(10). 1315–1321. 3 indexed citations

Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations

Hirsh, Vera, Luis Paz‐Ares, Michael Boyer, et al.. (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(19). 2667–2674. 116 indexed citations

Underhill, Craig, Michael Millward, Sandra J. Meech, et al.. (2009). Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. Journal of Clinical Oncology. 27(15_suppl). 3046–3046. 3 indexed citations

Manegold, Christian, Donald Gravenor, Donald Woytowitz, et al.. (2008). Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(24). 3979–3986. 129 indexed citations

Manegold, C., et al.. (2008). Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8017–8017. 14 indexed citations

10.

Readett, David, et al.. (2007). PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S461–S461. 5 indexed citations

11.

Richards, Michael J., et al.. (1998). Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Archives of Disease in Childhood Fetal & Neonatal. 79(3). F215–F217. 26 indexed citations

12.

Irving, William L., et al.. (1995). Hepatitis C virus infection in multi‐transfused children with haematological malignancy. British Journal of Haematology. 91(2). 480–482. 12 indexed citations

13.

Readett, David, et al.. (1991). Nocturnal enuresis in normal Jamaican children. Implications for therapy.. PubMed. 40(4). 181–4. 27 indexed citations

14.

Readett, David, J Morris, & G. R. Serjeant. (1990). Nocturnal enuresis in sickle cell haemoglobinopathies.. Archives of Disease in Childhood. 65(3). 290–293. 21 indexed citations

15.

Readett, David, J Morris, & G. R. Serjeant. (1990). Determinants of nocturnal enuresis in homozygous sickle cell disease.. Archives of Disease in Childhood. 65(6). 615–618. 25 indexed citations

16.

Watson, Alan R., et al.. (1989). Dilemmas Associated With Antenatally Detected Urinary Tract Abnormalities. The Journal of Urology. 141(1). 210–211. 1 indexed citations

17.

Watson, Alan R., et al.. (1988). Dilemmas associated with antenatally detected urinary tract abnormalities.. Archives of Disease in Childhood. 63(7 Spec No). 719–722. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact